A large measurement gap
Cognition is central to health, recovery, performance, and safety, but practical objective measurement is still limited.
Investors
The measurement layer for brain performance
RetinaTek is building a task-evoked neurocognitive measurement platform, starting with RT-Focus as a planned near-term commercial wedge and expanding toward future regulated recovery-monitoring, clinical-development, and platform markets.
Cognitive function affects aging, recovery, performance, safety, and treatment response, yet practical measurement remains subjective, episodic, and noisy. RetinaTek's platform combines task-evoked eye tracking, pupil dynamics, manual responses, and stimulus timing to create objective, repeatable cognitive-performance measurement under controlled load.
The investment thesis
A differentiated technical approach
RETINA is task-evoked measurement, not passive gaze tracking or a digitized paper test.
A claims-disciplined commercial wedge
RT-Focus creates a planned near-term path to revenue through supervised cognitive-performance assessment without relying on disease-diagnostic claims.
A staged clinical-development path
Research deployments and future validation programs support the path toward regulated indications such as concussion/mTBI recovery-monitoring claims and adjacent CNS applications after appropriate validation and clearance.
Platform expansion potential
The same measurement architecture may extend into research endpoints, rehabilitation, cognitive aging, ADHD, MS, CNS trials, defense, occupational safety, and AI/data partnerships through appropriate research, validation, regulatory, and market-development pathways.
The commercial wedge de-risks the clinical platform
RT-Focus is RetinaTek's first planned commercial product for supervised cognitive performance assessment in premium clinical and performance-oriented settings. RetinaTek is engaging FDA through the Q-submission process to confirm the appropriate regulatory pathway. It is designed to be a real business: a practical product that can generate revenue, support deployment learning, and put RetinaTek's measurement platform into the hands of early customers.
But RT-Focus is not the full venture thesis. Its strategic role is to de-risk the larger opportunity by creating market traction, longitudinal measurement experience, report and workflow feedback, data infrastructure, and early revenue while RetinaTek builds toward higher-value regulated indications.
Near-term wedge: RT-Focus
- Premium clinical and performance-oriented settings
- Concierge, executive, longevity, and preventive medicine
- Cognitive aging and brain-performance baselining
- Repeat assessment over time
- Claims-disciplined commercial development
- Early revenue and deployment learning
Long-term upside: regulated and platform markets
- Future adult and pediatric concussion/mTBI recovery-monitoring claims
- ADHD, MS, and adjacent CNS clinical-development pathways after appropriate validation
- Rehabilitation and recovery-tracking research
- CNS biopharma endpoints
- Defense and human performance
- Occupational safety and platform partnerships
The wedge generates traction. The platform creates venture-scale upside.
Why the first product matters
The earliest commercial product does not need to carry the entire company. It needs to do something strategically valuable: generate revenue, validate workflow, prove customer willingness to adopt, and create the operating infrastructure required for future clinical markets.
Revenue before disease-specific claims
A claims-disciplined cognitive-performance product may create revenue while disease-specific regulated clinical claims are developed separately.
Real-world deployment learning
Clinic use reveals what works in administration, reporting, training, support, workflow, and repeat testing.
Longitudinal measurement infrastructure
Repeat assessments create experience with cognitive-performance measurement over time, which is central to future recovery-monitoring markets after appropriate validation and clearance.
Customer credibility
Paid deployments strengthen conversations with investors, strategic partners, researchers, and clinical-development collaborators.
Product and data operations
Commercial use helps mature the software, data pipeline, quality controls, report design, and service model.
Reduced financing risk
Early revenue and deployment evidence can reduce reliance on purely speculative funding while future indications are validated.
Why now
Eye-tracking hardware has matured
Commercial headset hardware makes controlled, high-quality measurement increasingly deployable.
Cognitive health demand is rising
Aging, fatigue, attention, concussion-related research, and performance concerns are becoming mainstream clinical and consumer priorities.
Premium clinics need differentiated offerings
Concierge, executive, longevity, and preventive medicine practices are looking for objective brain-performance tools.
CNS trials need better endpoints
Biopharma and academic researchers need repeatable, low-burden digital endpoints for cognitive change and treatment response.
Future recovery monitoring remains under-measured
Concussion and mTBI research and clinical development need objective ways to study recovery trajectory, not just one-time assessment.
AI needs structured labels
Future cognitive-state models need validated, task-evoked labels and longitudinal multimodal datasets.
Why this is not commodity eye tracking
The RetinaTek moat is not the headset. It is the patented task-evoked measurement approach, synchronized multimodal data architecture, scoring and quality-control layer, and evidence base linking these measures to cognitive, clinical, imaging, and performance outcomes.
Patented task-evoked approach
Protected intellectual property around enhanced neuropsychological assessment using eye tracking and cognitive task paradigms.
Federally funded validation
Developed through more than a decade of federally supported military and clinical research.
Multimodal data architecture
Combines eye movements, pupil dynamics, manual responses, and stimulus timing into a unified measurement system.
Proprietary scoring and quality controls
Feature extraction, data-quality logic, score construction, and interpretation models remain proprietary.
Biological and clinical evidence base
Published research supports construct validity, cognitive-load sensitivity, performance-validity utility, and MRI-linked biological plausibility.
Longitudinal data potential
Repeated measurement across research and commercial deployments can create a differentiated dataset for future clinical and platform applications.
Regulated upside: future recovery monitoring, not just diagnosis
Diagnosis is important, but the larger future clinical-development opportunity is repeatable recovery-monitoring: helping determine whether a person is recovering as expected, plateauing, worsening, or likely to benefit from additional evaluation or intervention after appropriate validation and clearance.
RetinaTek is pursuing NIH applications and partner-supported validation programs for adult and pediatric concussion/mTBI, with future expansion potential in ADHD, MS, neurodegenerative conditions, rehabilitation, and other CNS markets after appropriate validation and market development. Future clinical claims require appropriate validation and regulatory clearance.
Adult and pediatric concussion/mTBI
Initial future regulated focus on recovery trajectory, treatment response, and return-to-activity decision support after appropriate validation and clearance.
ADHD and attention-related pathways
Potential future clinical-development applications where objective attention, inhibition, and consistency measures may add value.
MS and cognitive fatigue
Potential future clinical-development work involving processing speed, cognitive fatigue, treatment response, and disease-related cognitive change after appropriate validation.
Broader CNS expansion
Future applications may include rehabilitation, neurodegenerative conditions, Long COVID, medication effects, and CNS clinical trial endpoints.
Revenue architecture
RT-Focus commercial revenue
Per-assessment, subscription, site-license, or bundled premium-clinic models for supervised cognitive performance assessment.
Research deployments
Paid research systems, endpoint-development studies, clinical-development collaborations, and sponsored validation work.
Future regulated clinical platform
Per-test or SaaS model for validated recovery-monitoring and clinical decision-support applications after appropriate validation and clearance.
Strategic and platform partnerships
Potential future opportunities in hardware integrations, CNS endpoints, longitudinal datasets, AI/data partnerships, and international markets.
What seed capital unlocks
Seed capital is intended to move RetinaTek from validated science to commercial deployment and clinical-development readiness.
RT-Focus regulatory-pathway planning
Prepare RT-Focus for planned early commercial deployments, subject to regulatory-pathway confirmation and claims review.
Paid deployment traction
Generate early revenue, workflow evidence, customer feedback, and repeat-testing experience.
Research and clinical-development deployments
Expand studies and collaborations using objective neurocognitive endpoints.
Data and software infrastructure
Mature the platform architecture, reporting, data pipeline, security, and longitudinal measurement infrastructure.
Quality and regulatory readiness
Build documentation, usability, risk management, data integrity, and quality controls for future regulated development.
FDA Q-submission engagement
Engage FDA through the Q-submission process to confirm the appropriate regulatory pathway for RT-Focus.
Adult and pediatric validation strategy
Pursue NIH applications, SBIR submissions, and partner-supported validation programs for future concussion/mTBI recovery-monitoring indications.
Near-term value inflection points
RT-Focus regulatory-pathway feedback and early-access planning
First paid clinic deployments, subject to pathway confirmation and claims controls
Research and clinical-development partnerships
NIH/SBIR submissions and potential awards
Product/software lock for future validation
FDA Q-submission pathway feedback
Longitudinal dataset growth
Strategic platform partnership discussions
Adult and pediatric concussion/mTBI validation launch planning
Investor materials and claims boundaries
RETINA is an in-development neurocognitive measurement platform. RT-Focus is a planned supervised cognitive performance assessment, and RetinaTek is engaging FDA through the Q-submission process to confirm the appropriate regulatory pathway. Current public materials do not claim that RETINA or RT-Focus is FDA-cleared, FDA-approved, or authorized for diagnostic use. Disease-specific diagnostic or monitoring claims require appropriate validation and regulatory clearance.
Interested in RetinaTek's seed round?
RetinaTek is engaging investors who understand digital health, medical devices, cognitive health, human performance, CNS markets, and regulated software. The company is building a real early commercial business while pursuing the larger opportunity: objective, repeatable neurocognitive measurement across future clinical and platform markets.